Preliminary study of the association of serum irisin levels with poor sleep quality in rheumatoid arthritis patients

Gamal, Rania M.; Mohamed, Mai; Hammam, Nevin; Fetoh, Noha Abo El; Rashed, Ahmed M.; Fürst, Daniel E.

doi:10.1016/j.sleep.2019.10.021

Cited by 15 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this respect, other authors also reported that higher serum levels of irisin are related to more favorable lipid profiles in the general population (34,39). Accordingly, both results are in agreement with the atheroprotective and anti-inflammatory role proposed for irisin in pathological contexts different from axSpA (19)(20)(21)(22)(23)(24). In this regard, a relevant role for irisin against vascular inflammation, endothelial cell dysfunction, oxidative stress and plaque progression has been described (20)(21)(22)(23).…”

Section: Discussionsupporting

confidence: 77%

“…This molecule has been reported to play a critical beneficial role in several processes such as inflammation, angiogenesis, oxidative stress, endothelial cell dysfunction, and lipid and bone metabolism (11)(12)(13)(14)(15)(16)(17)(18)(19). In particular, it has been described that irisin plays key roles against vascular inflammation by inhibiting the recruitment of inflammatory cells to the atherosclerotic lesions and also inducing the switch from the proinflammatory (M1) phenotype of macrophages to the antiinflammatory (M2) phenotype (19)(20)(21)(22)(23). In addition, previous studies reported that irisin downregulates other proinflammatory pathways, suppressing thereby the secretion of Abbreviations: AI, atherogenic index; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASMI, Bath Ankylosing Spondylitis Metrology Index; CI, confidence interval; cIMT, carotid intimamedia thickness; CRP, C-reactive protein; CV, cardiovascular; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HLA, Human leukocyte antigen; IQR, interquartile range; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; SD, standard deviation; US, ultrasound; VAS, visual analogue scale.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis

et al. 2022

View full text Add to dashboard Cite

IntroductionPatients with axial spondyloarthritis (axSpA) have a high disease burden mainly due to the rheumatic disease itself, and also exhibit accelerated atherosclerosis, that leads to a higher incidence of cardiovascular (CV) disease. Accordingly, the identification of biomarkers of CV risk and inflammation in axSpA patients is clinically relevant. In this sense, given the beneficial functions exerted by the adipomyokine irisin in processes related to CV disease and inflammation, our aim was to assess, for the first time, the role of irisin as a genetic and serological biomarker of subclinical atherosclerosis, CV risk and disease severity in axSpA patients.MethodsA large cohort of 725 Spanish patients with axSpA was included. Subclinical atherosclerosis (presence of plaques and abnormal carotid intima-media thickness values) was evaluated by carotid ultrasound. Four irisin polymorphisms (rs16835198 G/T, rs3480 A/G, rs726344 G/A, and rs1570569 G/T) were genotyped by TaqMan probes. Additionally, serum irisin levels were determined by ELISA.ResultsLow irisin levels were linked to the presence of plaques (p=0.002) and atherogenic index values ≥4 (p=0.01). Serum irisin were positively correlated with C-peptide levels (p<0.001) and negatively correlated with visual analogue scale and Bath Ankylosing Spondylitis Metrology Index (p<0.05 in all the cases). Moreover, lower irisin levels were observed in patients with sacroiliitis and in those with a negative HLA-B27 status (p<0.001 and p=0.006, respectively), as well as in those treated with non-steroidal anti-inflammatory drugs and conventional disease-modifying antirheumatic drugs (p<0.001 and p=0.002, respectively). Interestingly, the TT genotype and the T allele of rs16835198 were less frequent in axSpA patients with ASDAS >2.1 (Odds Ratio (OR): 0.48 [0.28-0.83] and OR: 0.73 [0.57-0.92], respectively, p=0.01 in both cases). Additionally, the frequency of rs1570569 T allele was higher in these patients (OR: 1.46 [1.08-1.97], p=0.01). Furthermore, the GGGT haplotype was more frequent in patients with ASDAS values >2.1 (OR: 1.73 [1.13-2.66], p=0.01).ConclusionsOur results indicate that low serum irisin levels could be indicators of the presence of subclinical atherosclerosis, high CV risk and more severe disease in axSpA patients. In addition, irisin may also constitute a genetic biomarker of disease activity in axSpA.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Introductionmentioning

confidence: 99%

Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Exercise promotes irisin expression and induces anti-inflammatory effects ( Wiecek et al, 2018 ). Serum irisin levels are negatively correlated with inflammation-related symptoms, such as disease duration, severity evaluation, and stiffness duration in rheumatoid arthritis patients ( Gamal et al, 2019 ). Anti-inflammatory property of irisin is associated with the downregulation of the Toll-like receptor 4 (TLR4)/myeloid differentiation primary response protein 88 (MyD88) downstream pathway and decreased the phosphorylation of NF-κB, consequently decreased phosphorylation and activation of crucial pro-inflammatory cytokines ( Mazur-Bialy et al, 2017 ).…”

Section: Role Of Exercise In Regulating Chronic Diseasesmentioning

confidence: 99%

The Role of Irisin in Exercise-Mediated Bone Health

Liu

Guo

Chen

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Exercise training promotes physical and bone health, and is the first choice of non-drug strategies that help to improve the prognosis and complications of many chronic diseases. Irisin is a newly discovered peptide hormone that modulates energy metabolism and skeletal muscle mass. Here, we discuss the role of irisin in bone metabolism via exercise-induced mechanical forces regulation. In addition, the role of irisin in pathological bone loss and other chronic diseases is also reviewed. Notably, irisin appears to be a key determinant of bone mineral status and thus may serve as a novel biomarker for bone metabolism. Interestingly, the secretion of irisin appears to be mediated by different forms of exercise and pathological conditions such as diabetes, obesity, and inflammation. Understanding the mechanism by which irisin is regulated and how it regulates skeletal metabolism via osteoclast and osteoblast activities will be an important step toward applying new knowledge of irisin to the treatment and prevention of bone diseases such as osteolysis and other chronic disorders.

show abstract

“…Gamal et al [ 167 ] conducted a preliminary cross-sectional study with 58 RA patients matched with 30 healthy controls to evaluate the association between serum irisin concentrations and the quality of sleep as well as to assess the disease activity of RA combined with irisin levels. The results showed that irisin levels were decreased among RA individuals and correlated inversely with the disease duration and morning stiffness in RA diseased.…”

Section: General Aspects Of Ra and The Role Of Myokines Osteokines Ad...mentioning

confidence: 99%

Organokines in Rheumatoid Arthritis: A Critical Review

Laurindo

Maio

Barbalho

et al. 2022

IJMS

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects the joints. Organokines can produce beneficial or harmful effects in this condition. Among RA patients, organokines have been associated with increased inflammation and cartilage degradation due to augmented cytokines and metalloproteinases production, respectively. This study aimed to perform a review to investigate the role of adipokines, osteokines, myokines, and hepatokines on RA progression. PubMed, Embase, Google Scholar, and Cochrane were searched, and 18 studies were selected, comprising more than 17,000 RA patients. Changes in the pattern of organokines secretion were identified, and these could directly or indirectly contribute to aggravating RA, promoting articular alterations, and predicting the disease activity. In addition, organokines have been implicated in higher radiographic damage, immune dysregulation, and angiogenesis. These can also act as RA potent regulators of cells proliferation, differentiation, and apoptosis, controlling osteoclasts, chondrocytes, and fibroblasts as well as immune cells chemotaxis to RA sites. Although much is already known, much more is still unknown, principally about the roles of organokines in the occurrence of RA extra-articular manifestations.

show abstract

Preliminary study of the association of serum irisin levels with poor sleep quality in rheumatoid arthritis patients

Cited by 15 publications

References 36 publications

Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis

Irisin as a Novel Biomarker of Subclinical Atherosclerosis, Cardiovascular Risk and Severe Disease in Axial Spondyloarthritis

The Role of Irisin in Exercise-Mediated Bone Health

Organokines in Rheumatoid Arthritis: A Critical Review

Contact Info

Product

Resources

About